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Introduction: 
The World Health Organisation (WHO) estimates that cardiovascular diseases are the 
leading cause of death globally, causing 17.5 million deaths in 2012. Of these, stroke was 
the second leading cause of global death[1]. Cerebrovascular disease is the most common 
cause of neurological disability in older adults, and contributes substantially to dementia. 
Stroke incidence rates are increasing rapidly in low-income and middle-income countries, 
and absolute numbers are rising in high-income countries due to increasing life-
expectancy[2]. The American Heart Association estimates that annual total (direct and 
indirect) costs of stroke were $34 Billion in 2011[3].  
 
Primary and secondary prevention of early and late recurrent events is a major 
strategy to reduce the overall burden of stroke. Anti-thrombotic, lipid-lowering, anti-
hypertensive therapy and lifestyle modification are proven approaches for stroke 
prevention[4]. Recent data indicate that atherosclerotic plaque inflammation may be an 
important contributor to plaque destabilisation and thrombo-embolic events. In patients 
with coronary artery disease, clinical trials of anti-inflammatory therapies to prevent 
subsequent vascular events are under way. We aimed to review the medical literature 
relating to plaque inflammation in cerebrovascular disease, with a specific focus on clinical 
trials targeting atherosclerotic inflammation for secondary stroke prevention. 
 
 
Importance of atherosclerosis in cerebrovascular disease: 
Atherosclerosis of the aorta, cervical, or intracranial large or small arteries is a 
major pathophysiological finding causally related to or associated with a large proportion 
of ischemic stroke. This view is supported by four main lines of evidence. 
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First, direct imaging evidence of atherosclerotic narrowing of the aorta or cranio-
cervical arterial system is common in patients with ischaemic stroke or transient ischaemic 
attack (TIA). Population-based and hospital studies have reported ipsilateral carotid 
stenosis (≥50% arterial lumen narrowing) in 12-20% of ischaemic stroke patients[5-10], 
with intracranial atherosclerosis (ICAS) in a further 8-10% of North American/European 
and 30-50% of Asian patients[11,12]. Symptomatic ICAS is associated with pathological 
features of plaque instability (rupture, inflammation) and inflammatory markers such as 
CRP and leucocyte count predict recurrent vascular events in patients with ICAS[13-17]. 
Recent data also suggest that arterial stenosis of less than 50% may play an aetiological role 
in acute ischaemic stroke. A cross sectional study of 85 Embolic Stroke Unknown Source 
(ESUS) cases imaged by CT angiography showed that plaque 3-5 mm in thickness was 
present ipsilateral to the stroke in 11-35% of cases versus 1-15% on the contralateral side. 
There was a poor correlation between plaque volume and degree of stenosis[18].  
Second, indirect evidence suggests that atherogenic embolism originating from the 
arterial system is likely to contribute to a substantial proportion of patients with stroke in 
whom no direct mechanism is identified, which account for 18-35% of all stroke in 
registries and clinical trials[19]In the EMBRACE trial, paroxysmal atrial fibrillation (AF) 
was detected in only 16% at 90 days of patients with cryptogenic stroke or transient 
ischaemic attack (TIA) who underwent prolonged cardiac monitoring[20]. In the 
CRYSTAL-AF, trial AF was detected in 9% of cryptogenic stroke/TIA patients at 6 months 
and 30% by 36 months[21]. However, it is unclear whether late detection of AF in 
CRYSTAL-AF was causally related to the initial event. Taken together, these data suggest 
that a substantial proportion of cryptogenic stroke/TIA cases were unrelated to cardiac 
embolism.  
In the North Dublin Population Stroke Study, 73% of patients with TOAST-classified stroke 
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of unidentified etiology had evidence of aortic or cranio-cervical atherosclerosis defined by 
the ASCO classification[22]. Thick (>4mm) plaque of the aortic arch is also frequent in 
patients with cryptogenic stroke, with a prevalence of 28% reported in one prospective 
study[23]. In this study, plaque >4mm was almost 5 times more frequent in patients with 
cryptogenic stroke compared with those with stroke of identified cause (adjusted odds ratio 
4.7, CI 2.2-10.1), supporting the hypothesis that aortogenic embolism may have accounted 
for symptoms. Further indirect evidence supporting a role of aortogenic embolism may 
emerge from ongoing trials currently evaluating rivaroxaban and dabigatran for secondary 
prevention in patients with embolic stroke of undetermined source (ESUS). 
 
Third, micro-atheroma is an important contributor to ischaemic disease of cerebral 
small vessels (arteries and arterioles), which accounts for up to 20% of stroke and is a 
major contributor to dementia[24]. Although the pathophysiology of cerebral ischaemic 
small vessel disease is varied and not fully understood, existing data suggest two common 
mechanisms[24]: (1) micro-atheroma of larger penetrating arterioles, causing single, 
frequently-symptomatic acute lacunar infarcts, and (2) lipohyalinosis (‘arteriolosclerosis’), 
more frequently associated with diffuse white matter hyperintensity on neuroimaging and 
neuropathological evidence of cerebral demyelination. 
 
Fourth, randomised clinical trials in patients with non-cardioembolic stroke and TIA 
have demonstrated benefit of targeting plaque-related lipid accumulation with high-dose 
atorvastatin and platelet activation to prevent recurrent stroke and coronary events[25-27]. 
 
High residual vascular risk in stroke survivors: 
Although sub-optimal secondary prevention is common among survivors of stroke and 
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TIA[28, 29], the residual risk of recurrent stroke, coronary events and vascular death is 
substantial even among those treated with high rates of established secondary preventive 
medications. Data from recent clinical trials and stroke registries indicate a recurrent stroke 
risk of 2.5-4% per year in patients treated with high rates of statin and antiplatelet therapies 
after stroke and TIA[30-33]. A systematic review reported a cumulative pooled recurrent 
stroke risk of 11.1% at one year and 26.4% at 5 years[34]. The risk of myocardial 
infarction and vascular death is also substantial in long-term stroke/TIA survivors. In a 
systematic review (39 studies, 65,996 patients), Touze found a 2.1%/year rate of non-
stroke vascular death and 0.9%/year risk of non-fatal myocardial infarction (MI) in stroke 
survivors[35]. Early stroke recurrence risk after first stroke and TIA is highest in patients 
with large-artery atherosclerosis of the cervical carotid arteries, intracranial vessels, or 
posterior circulation, compared with other stroke mechanisms[33. 36-39]. The mechanisms 
explaining this residual risk are unclear. However, evidence from multiple sources support 
the hypothesis that inflammation-related plaque instability may be an important 
contributing factor[40].  
 
Inflammation and pathophysiology of atherosclerotic plaque: 
Accumulating evidence supports the view that inflammation is of key importance in the 
pathophysiology of atherosclerotic plaque destabilisation and thrombo-embolism[41-43]. A 
large body of experimental data indicates that inflammatory cells are involved in all stages 
of atherosclerosis development. Trans-endothelial migration of circulating monocytes is a 
key event in the initiation of atherosclerotic plaque, mediated by surface adhesion molecule 
expression in response to endothelial stimuli such as arterial tension, non-laminar flow, 
cigarette smoke constituents, and angiotensin 2. Retention of low-density lipoprotein 
(LDL) lipids in the extracellular matrix of the arterial wall is accompanied by 
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differentiation of monocytes and lipid uptake to lipid-laden ‘foamy’ macrophages. 
Differentiation of macrophages into pro-inflammatory subsets (M1 macrophages) results in 
local expression of pro-inflammatory cytokines, particularly interleukin 1-beta (IL 1β) and 
tumour necrosis factor-alpha (TNF-α). Cytokines such as platelet-derived growth factor 
(PDGF) promote recruitment and proliferation of smooth muscle cells into the endothelial 
cell layer, which express matrix proteins such as collagen and elastin. As plaque 
progression continues, a fibrous cap of endothelial cells mainly smooth muscle cells and 
collagen develops, overlying a plaque matrix comprising monocyte-macrophages, 
connective tissue proteins, extracellular lipids, smooth muscle cells, and neo-
vascularisation. Local ingress of T-helper (T-H1) cells produce pro-inflammatory 
cytokines, particularly interferon-gamma (IFN-γ), while T-regulatory cells produce 
inhibitory cytokines such as IL-10 and TGF-β. Apoptosis of macrophages and SMCs 
releases lipid and cellular debris within the extracellular matrix, to form a lipid-rich 
necrotic core containing pro-coagulant tissue factor. Expression of cytokines and 
collagenolytic enzymes such as metalloproteinases from macrophages and other cells 
contributes to erosion and rupture of the fibrous cap, exposure of circulating platelets and 
coagulation factors to the pro-thrombotic core, and subsequent thrombo-embolism. 
 
 
Association of stroke with inflammation from clinical studies: 
Clinical and epidemiological data supporting the association of plaque inflammation with 
stroke are derived from six main sources: (1) Epidemiological studies of inflammatory 
biomarkers (2) Epidemiological studies of the association of infection with stroke risk (3) 
Genetic epidemiological studies of gene polymorphisms in inflammation-pathway proteins 
(4) Clinical-pathological studies (5) Plaque imaging studies (6) Randomised clinical trials 
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of anti-inflammatory agents in vascular disease.  
 
(1) Epidemiological studies of inflammatory biomarkers: 
The central inflammatory pathway is characterised by the key cytokines interleukin-1, 
interleukin-6 [IL-6], and tumor-necrosis factor α [TNF-α]. Epidemiological studies have 
consistently described dose-dependent associations between circulating blood biomarkers 
of this pathway and vascular disease, including stroke. Such biomarkers can be considered 
as ‘downstream’ (eg. C-reactive protein [CRP]) and ‘up-stream’ markers (eg. IL-6, TNF-
α])[43].  
The Emerging Risk Factors Collaboration have described the relationship between 
circulating CRP and incident stroke in 160,309 individuals without vascular disease in 
prospective studies[44]. After adjusting for age, sex, and study, a linear relationship was 
observed between circulating CRP and risk of ischaemic stroke, which remained (although  
attenuated) after further adjustment for existing vascular risk factors (Figure 1). The 
adjusted relative risk per 3-fold increase in CRP was 1.27 (95% CI 1.15-1.40). A similar 
relationship was observed for coronary disease.  
CRP is increased following acute stroke in response to tissue injury and infection, 
proportionate to the severity of the acute event[45]. In the post-acute phase, CRP 
remains elevated compared with control subjects, with greatest elevation in patients 
with large-artery stroke mechanisms. CRP has been reported to independently predict 
recurrent stroke risk in patients with stroke or TIA due to carotid or intracranial 
atherosclerosis[46,47]. Recently, CRP measured at baseline was reported to 
independently predict the risk of recurrent stroke and vascular events in the SPS3 and 
CHANCE trials. In 1244 patients with lacunar stroke in SPS3, baseline CRP was 
associated with a 2.32-fold increase in the adjusted hazard of recurrent stroke and 
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vascular events (highest versus lowest quartile)[48]. In 3044 patients with non-severe 
non-cardioembolic stroke in the Chinese CHANCE trial, patients in the highest CRP 
quartile measured at baseline had a 1.46-fold increase in the adjusted risk of early 
recurrent stroke at 90 days, and increased risk of stroke at 1 year[49]. In 1,232 patients 
with recent stroke/TIA in the Oxford Vascular Study, CRP measured in the acute 
phase was an independent predictor of 90-day stroke recurrence (adjusted hazard ratio 
1.15, CI 1.02-1.30)[50]. Broadly consistent findings have been observed with other 
inflammatory biomarkers, including fibrinogen and IL-6[50,51]. 
 
(2) Studies of association between infection and stroke risk: 
Inflammation of the cerebral arterial wall in response to direct infection by varicella zoster 
virus has long been recognized as a cause of ischaemic stroke. Other viruses (CMV, 
hepatitis B, hepatitis C, Epstein-Barr virus), fungal (aspergillus, histoplasma), and bacterial 
(syphilis, mycobacterium tuberculosis, H influenzae) may also trigger cerebral vasculitis 
and stroke, via direct arterial wall invasion, immune-complex deposition, or secondary 
cryoglobulinaemia[52-54]. These occur typically, although not exclusively, in immune-
suppressed patients. HIV has recently been associated with extensive remodeling of the 
cerebral arterial wall, although the role of inflammation in this process is unclear[55]. 
 
Epidemiological studies have reported associations between chronic infection and stroke 
risk. Infective agents have been diverse, including Chlamydia pneumoniae, H influenzae, H 
pylori, Herpes simplex 1 and 2, CMV, and Epstein Barr virus[56]. The Northern Manhattan 
Study reported an association (adjusted hazard ratio 1.39) between overall infectious 
burden, defined as cumulative exposure to several pre-specified infective agents, and first-
ever stroke risk[57]. However, this finding requires further confirmation, as other studies 
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have not demonstrated an association between chronic infectious burden and stroke 
risk[58,59]. Recent data suggests that acute infection may be associated with higher stroke 
risk. In an analysis from the Cardiovascular Health Study, Elkind and colleagues reported 
increased risk of first-ever stroke associated with hospital admission for treatment of 
infection, with greatest risk observed at earliest time-points[60]. The adjusted hazard ratio 
for stroke within 90 days of admission was 2.4 (CI 1.6-3.4). Further studies are required to 
definitively confirm this finding.  
 
(3)  Genetic epidemiology studies: 
Despite sophisticated analytical methods, the interpretation of epidemiological studies 
investigating blood biomarkers may be limited by residual confounding and ‘reverse 
causality’ (where sub-clinical disease may influence the biomarker levels). 
Epidemiological studies of gene variants affecting protein function in key pathways 
overcome these limitations, as by definition exposure is determined prior to the onset of 
disease.  
One such functional polymorphism exists in the IL-6 receptor gene, causing an alanine -to -
aspartate substitution at position 358 of the expressed protein, resulting in reduced 
membrane-bound IL-6 receptor, impaired IL-6 signalling, and reduced expression of 
downstream CRP and fibrinogen.  Two ‘Mendelian randomisation studies’ have reported 
associations of this polymorphism with reduced risk of coronary heart disease after 
adjusting for conventional risk factors, in a dose-dependent fashion depending on number of 
358Ala alleles inherited, with consistent effect sizes  (per allele, 3.4%, CI 1.8-5 and 5%, CI 
3-7)[61,62]. Similar reductions in CRP and fibrinogen were observed, supporting the 
biological plausibility of the findings. However, stroke was not reported as an outcome in 
these studies. Genome wide association studies in ischemic stroke patients with sufficiently 
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large sample sizes may elucidate the role of these variants in stroke. 
 
(4) Clinical-pathological studies: 
Pathological studies also support an association between plaque inflammation and 
clinical events. For example, an analysis of resected carotid plaque from 526 patients with 
symptomatic carotid stenosis in the Oxford Plaque Study found that 66% of patients had 
evidence of marked inflammation in resected plaque from the ipsilateral internal carotid 
artery, while 64% had other features of plaque instability (thin fibrous cap, large lipid 
core, cap rupture, or superficial thrombus)[63]. Extensive macrophage infiltration was 
independently associated with plaque rupture (adjusted odds ratio 3.52, p<0.001), as were 
cap thickness <200μm (OR 2.64), intraplaque haemorrhage (OR 2.65), and large lipid core 
(OR 4.03) (all ORs adjusted, p<0.001 for all).  
Similar findings were observed in a smaller study investigating the relationship of 
plaque inflammation with early recurrent stroke[64]. In 44 consecutive patients with 
ipsilateral carotid stenosis and TIA/ischaemic stroke who had endarterectomy within 10 
days (interquartile range 7-17 days), early stroke recurrence pre-endarterectomy was 
associated with extensive macrophage and lymphocyte infiltration (Oxford Plaque Score 
≥3), low fibrous content, ≥25% cap disruption, and plaque neovascularization. After 
adjustment for age and degree of stenosis, high macrophage density was the only 
independent predictor of early stroke recurrence (adjusted HR 9.0, p=0.04). 
Matrix metalloproteinases (MMPs) are proteolytic enzymes for which sub-
endothelial matrix collagen and elastin are known substrates. In patients with small artery 
disease, increased inflammatory cells (macrophages, activated microglia) expressing 
MMPs are present around affected arterioles and areas of ischemic demyelination and 
MMP-9 is increased in cerebrospinal fluid[65,66]. 
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(5) Plaque imaging studies: 
Positron emission tomography using 18-fluorodeoxyglucose (FDG-PET) is a validated 
technique for imaging plaque metabolic activity, mainly related to inflammatory monocyte-
macrophage activity. Tawakol reported high FDG uptake in symptomatic carotid plaque, 
with high (r=0.89) correlation with plaque macrophage density[67]. Cross-sectional studies 
have established that plaque FDG uptake is correlated with other markers of plaque 
instability, such as micro-embolic signals on transcranial Doppler ultrasound, unstable 
plaque morphology, and expression of inflammatory cytokines and proteases[68-70]. 
Longitudinal studies in patients who underwent whole-body PET for cancer screening have 
reported that aortic FDG uptake independently predicts late vascular events, including 
stroke. In 60 patients with recent stroke/TIA and ipsilateral carotid stenosis, we found that 
carotid plaque FDG uptake was an independent predictor of early pre-endarterectomy 
stroke recurrence, after adjusting for age and degree of stenosis (adjusted HR 6.1, CI 1.3-
28.8, p=0.02) (Figure 2)[71]. The 90-day stroke recurrence rate for patients in the highest 
FDG uptake tertile was 59% compared with 19% and 13% in the lowest tertiles (log-rank 
p=0.03) (Figure 3).  Other groups have reported similar findings[72,73]. An international 
multi-centre study (BIOVASC) is under way to test the validity of these findings in an 
independent cohort.  
 
(6)  Randomised trials in patients without cerebrovascular disease:  
In patients without clinical cerebrovascular disease, several randomised clinical 
trials testing the hypothesis that inhibiting inflammation may prevent cardiovascular events 
have been completed or are under way (Table 1).  In addition to their lipid-lowering effects, 
statins are known to influence other biological pathways (pleotropic effects) including anti-
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inflammatory effects.  Small studies have demonstrated reduction in blood biomarkers and 
plaque FDG uptake in a dose-dependent manner by statins[74,75]. In the JUPITER trial, 
17,802 patients without a history of vascular disease, low-normal LDL cholesterol, and 
CRP ≥2mg/L were randomly allocated to receive either rosuvastatin 20mg or placebo[76]. 
Rosuvastatin treatment reduced LDL by 50% and CRP by 37%. The trial was halted early 
due to benefit, with a relative risk reduction in major vascular events of 46% in 
rosuvastatin-treated patients. In a pre-specified secondary analysis, the relative risk 
reduction for stroke was 48% (p=0.002). However, the interpretation of these findings was 
unclear due to the non-specific effects of rosuvastatin on both inflammation and LDL 
metabolism.  
Other trials which targeted secretory lipoprotein-associated phospholipase A2 
(LpPLA2), which has been hypothesized to be implicated in atherosclerosis development using 
specific antagonists (darapladib, varespladib) did not show benefit in patients with recent or 
stable coronary disease[77-79].  However, as LpPLA-2 is not centrally involved in the classical 
IL1-IL6-TNFα inflammatory pathway, these results should be interpreted with caution. 
Clinical trials using specific and direct anti-inflammatory interventions are under 
way in non-stroke populations (Table)[40,43]. In CANTOS, canukinumab (an interleukin-
1β antagonist) is under evaluation in 10,000 patients with stable coronary disease selected 
on the basis of CRP ≥2mg/L. The National Institutes of Health-funded Cardiovascular 
Inflammation Reduction Trial (CIRT) is comparing low-dose weekly methotrexate (15 or 
20mg per week) with placebo plus recommended care in 7,000 patients with stable 
coronary disease and diabetes or metabolic syndrome. In Australia, the LoDoCo2 trial is 
examining the efficacy of low-dose colchicine compared with placebo in addition to 
usual care in patients with stable coronary disease (see below). An ongoing trial is 
comparing the IL-6 antagonist tocilizumab with entanercept for prevention of major 
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cardiovascular events in patients with rheumatoid arthritis and cardiovascular risk 
factors. 
 
Randomised trials of anti-inflammatory treatments for secondary stroke prevention: 
To assess the literature of trials of anti-inflammatory agents for stroke prevention, we 
conducted a systematic review of published data. We searched MEDLINE for completed 
published trials and the Clinicaltrials.gov registry for ongoing trials. Pre-specified inclusion 
criteria were: (1) randomised controlled trials testing the addition of anti-inflammatory agents 
to standard care in patients with clinical cerebrovascular disease (study size 100 patients or 
more with at least 80% of included patients with stroke/TIA); (2) inclusion of stroke as a 
primary or secondary outcome measure; (3) inclusion of adults only (age ≥18 years); (4)  
English language publication; (5) publication year 1966-July 2016. The initial search strategy 
(Web-appendix) revealed 453 studies.  However, after review of abstracts, only a single 
ongoing trial (CONVINCE) testing low-dose colchicine for secondary prevention in patients 
with clinical cerebrovascular disease was identified.  
 
 
 
Crystal-induced inflammation and atherosclerosis:  
Crystallised extracellular cholesterol has long been recognized as a common feature 
of atherosclerotic plaque, but was often considered as a bystander phenomenon in plaque 
development. Recent experimental and clinical-pathological studies have shown that 
microscopic cholesterol crystals form very early in atherosclerotic plaque development, 
and may be a potent inflammatory stimulus for neutrophils and macrophages. Studies in 
ApoE-deficient mice have demonstrated that cholesterol crystals activate monocytes-
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macrophages via the intracellular nucleotide-binding leucine-rich repeat-containing pyrin 
receptor (NLRP) inflammasome protein complex. This causes increased IL-1β expression, 
which is known as a key event in the initiation of local and systemic inflammatory 
cascades, evidenced by elevated IL-6 and CRP[80-82]. These important observations 
provide direct evidence linking plaque lipid metabolism and inflammation. Indirect support 
for these findings in humans is provided by a PET study in patients with symptomatic 
carotid stenosis, where 18-FDG uptake in symptomatic plaque was associated with total 
and LDL cholesterol, and inversely associated with HDL cholesterol, after adjustment for 
confounding variables[83].  
 
Uric acid is a product of purine metabolism which undergoes hepatic and renal elimination in 
vivo. Uric acid is a potent antioxidant with neuroprotective effects in animal models, and 
established safety in humans[84]. However, hyperuricaemia is strongly associated with 
atherosclerosis risk factors, such as hypertension, renal impairment, obesity, metabolic 
syndrome and ethanol excess[85]. In epidemiological studies, serum urate has been 
associated with inflammatory blood biomarkers, suggesting that hyperuricaemia may 
predispose to a pro-inflammatory state[86,87]. Some studies have described associations 
between hyperuricaemia and subclinical markers of atherosclerosis, such as carotid intima-
media thickness and coronary artery calcification burden[88]. However, these associations 
have not persisted after adjustment for vascular risk factors, raising the possibility that uric 
acid may be a risk marker rather than a causal factor. Data are conflicting regarding the 
association between uric acid and cardiovascular events, including stroke. Several studies 
have also reported positive associations. For example, in the Rotterdam study, the hazard 
ratio of ischaemic stroke was 1.77 (CI 1.1-2.83) in the fifth compared with the first quintile of 
uric acid, with only minimal attenuation after adjustment for vascular risk factors[89]. 
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However other studies, including the Framingham and ARIC studies, have not replicated 
these findings[90,91].  
 
In gout, monosodium urate crystals are deposited in joints and bursae, causing activation of 
the NLRP inflammasome, IL-1β generation, and both local and systemic inflammation. 
Crystal-induced inflammation, via either cholesterol and/or monosodium urate crystals, may 
be a common mechanism underlying the associations between inflammation, lipid 
metabolism, and hyperuricaemia.  
 
Potential of colchicine for prevention of atherosclerotic events:  
Colchicine has been a mainstay of treatment for goutfor centuries[92,93].  Although 
traditionally high-dose colchicine was associated with gastro-intestinal problems when 
used for acute gout flares, recent guidelines have recommended that similar efficacy may 
be achieved with major improvements in tolerability when lower doses are used[92]. 
Long-term low-dose colchicine is safe and effective for gout prevention , and has been a 
corner-stone of treatment of Bechet’s Disease and Familial Mediterranean Fever for 
decades[93]. 
 
Via binding to α- and β-tubulin proteins, colchicine has multiple anti-inflammatory 
properties including inhibition of microtubule polymerization, with inhibition of leucocyte 
rolling and endothelial adhesion, impaired leucocyte motility, phagocytosis, and cytokine 
secretion. It inhibits crystal-induced activation of the NLRP inflammasome, thus 
inhibiting caspase-1 proteolysis and interleukin-1β secretion in monocyte-macrophages. 
 
Observational data report lower rates of coronary disease in gout and FMF associated with 
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colchicine therapy[94].  In patients with stable coronary atherosclerosis treated with low-dose 
colchicine, statins, and antiplatelet agents, CRP was reduced by 60%, but was unchanged in 
controls (p=0.002)[95]. In the LoDoCo randomised trial, 532 patients with chronic stable 
coronary disease were randomised to the lowest-available dose of colchicine (0.5mg/day) or 
usual care[96]. Almost all were taking antiplatelet agents and high-dose statins at baseline, 
and anti-hypertensive therapy as-indicated. Over a median follow-up of 36 months, the risk of 
major cardiovascular events was reduced by 67% in patients treated with low-dose colchicine 
(HR 0.33, CI 0.18-0.59, p<0.001) (Figure 4). Only 5 stroke events occurred (as expected in 
this patient sample), but the direction of benefit for stroke was similar to that for coronary 
events (4 strokes in controls versus 1 in colchicine group, p=0.18).  Colchicine had an 
excellent safety profile. The commonest adverse effect was intestinal upset (2.5%) with 
myalgia in 2 patients (0.9%) and myositis, rash, itch, alopecia, or peripheral neuropathy 
reported in 1 patient each (<0.5%) and no excess of death observed.  Recent trials have also 
demonstrated benefit of low-dose colchicine (0.5-1mg/day) for prevention of recurrent 
pericarditis and reduced infarct size when used acutely in patients with ST-elevation 
myocardial infarction[97,98]. 
 
A 2016 Cochrane systematic review has investigated the safety and benefits of long term 
colchicine use with particular emphasis on cardiovascular disease[99]. It included 39 trials 
overall of 4992 patients, and 4 trials of 1230 patients with heart disease. The risk of 
myocardial infarction was reduced by 80% (relative risk 0.2, CI 0.07-0.57, 2 trials, 652 
patients, moderate quality evidence). No increased risk of serious adverse events was 
observed. Colchicine was associated with increased GI intolerance, generally mild and short-
lived.  
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CONVINCE: Can anti-inflammatory therapy with colchicine prevent recurrent stroke?  
 
The underlying pathophysiology of recurrent vascular events in patients with non- 
cardioembolic stroke is likely to resemble that in patients with coronary artery disease. 
Informed by the growing body of experimental and clinical data supporting a rationale for 
treatment with colchicine in vascular disease, the CONVINCE trial will test the hypothesis 
that daily low-dose colchicine (0.5mg/day) combined with usual care (lifestyle advice plus 
antiplatelet, antihypertensive, and lipid-lowering therapy) will have benefit for prevention 
of recurrent stroke and major vascular events compared with usual care alone[100]. Similar 
to other stroke secondary prevention trials of antiplatelet and lipid-lowering therapy, 
CONVINCE will include patients with non-severe (modified Rankin score 3 or less) stroke 
or TIA, randomised between 72 hours and 28 days of symptom onset and followed for a 
median of 36 months. Patients with cardioembolic stroke/TIA, those with other identified 
non-atherosclerotic stroke mechanisms (eg. arterial dissection), or contra-indication to 
colchicine therapy will be excluded. The tolerability and safety of colchicine will be closely 
monitored, with a pre-specified review after completion of randomization of the initial 10% 
of the trial sample (internal pilot ‘Vanguard’ stage).  
 
Conclusion: 
Atherosclerosis of different vessels has been associated with a large proportion of ischemic 
stroke. Growing evidence has emerged, based on experimental, epidemiological, and 
clinical data in recent years to support the hypothesis that inflammatory pathways are key 
mediators in the development of atherosclerosis, leading to stroke and other vascular 
events. This ‘inflammation hypothesis’ has been the basis of several clinical trials using 
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different agents in patients with coronary disease and colchicine has shown promising 
therapeutic potential to date. These findings require further study in ischemic stroke, and 
will be tested in the CONVINCE trial. Further trials are needed to improve our 
understanding of the role of atherosclerotic inflammation in stroke pathogenesis.  
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Trial Agent Target Included Result 
JUPITER Rosuvastatin   Multiple No cardiovascular 
disease, no indication 
for statins, CRP ≥ 
2mg/L 
Completed. Relative 
risk reduction (RRR) 
46% in MACE 
(p<0.00001) 
LoDoCo Colchicine Multiple Stable CAD  Completed. Relative 
risk reduction (RRR) 
67% in MACE (p<0.001) 
CIRT Low-dose 
methotrexate (15 
or 20mg/wk) plus 
standard 
treatment  
Multiple Stable CAD (MI<5 yr), 
T2DM, met syndrome 
Ongoing 
CANTOS Canakinumab IL-1B Stable CAD (MI>30d), 
CRP≥2 mg/L 
Ongoing 
ENTRACTE Tocilizumab IL-6 Rheumatoid arthritis 
with cardiovascular risk 
factors 
Ongoing 
LoDoCo2 Colchicine Multiple Stable CAD Ongoing 
CONVINCE Colchicine Multiple Non-cardioembolic 
stroke 
Ongoing 
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Figure Legends: 
Figure 1: 
Linear association of CRP with new coronary disease (top) and stroke (bottom) in 160,309 
individuals without vascular disease, adjusted for age, sex, and study (left, graphs A), and 
additionally for vascular risk factors (right, graphs B). Adjusted relative risk (RR) per 3-fold 
increase in CRP was 1.37 (CI 1.27-1.48) for coronary heart disease and 1.27 (CI 1.15-1.4) for 
ischaemic stroke 
 
Figure 2: 
2a (left image):  Axial CT angiogram of patient with left hemisphere TIA and internal carotid 
artery origin stenosis (arrow) 
2b (right image): Fused 18-FDG PET/CT image demonstrating focus of increased FDG 
uptake reflecting inflammatory hyper-metabolism at site of carotid mural plaque (arrow) 
 
Figure 3: 
Early recurrent stroke in patients with non-severe stroke or TIA and ipsilateral carotid 
stenosis, stratified by tertile of 18-FDG uptake in symptomatic plaque on PET/CT. Stroke 
recurrence rates were 59% in highest FDG uptake tertile vs 19% and 13% in the lowest and 
middle tertiles (log-rank p=0.03). In a Cox regression model adjusted for age and degree of 
stenosis the HR for stroke recurrence was 6.1 per 1 standard uptake value of plaque FDG 
activity (CI 1.3-28.8, p=0.02) 
 
Figure 4:  
Relative risk of major cardiovascular events in LoDoCo trial in patients with stable coronary 
disease treated with low-dose colchicine plus usual care compared with usual care alone 
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